RT Journal Article
SR Electronic
T1 China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design
JF Stroke and Vascular Neurology
JO Stroke Vasc Neurol
FD BMJ Publishing Group Ltd
SP 286
OP 290
DO 10.1136/svn-2020-000828
VO 6
IS 2
A1 Liu, Liping
A1 Wang, Yilong
A1 Xie, Xuewei
A1 Liu, Dacheng
A1 Wang, Aili
A1 Wang, Penglian
A1 Shen, Suwen
A1 Zhong, Chongke
A1 Wei, Yufei
A1 Xu, Tan
A1 Pan, Yuesong
A1 Jiang, Yong
A1 Meng, Xia
A1 Wang, David
A1 Zhang, Yonghong
A1 He, Jiang
A1 Wang, Yongjun
YR 2021
UL http://svn.bmj.com/content/6/2/286.abstract
AB Backgrounds Increased blood pressure (BP) for patients who had an acute ischaemic stroke is associated with poor functional outcome, however the optimal timing of antihypertensive therapy is unknown.Aims We aim to compare early antihypertensive treatment to delayed antihypertensive treatment for reducing the risk of composite major disability and mortality at 3 months in acute ischaemic stroke.Design The China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) trial is a multicentre, randomised, open-label, blinded-endpoints trial that will be conducted in 100 hospitals in China. The primary outcome is the composite of death and major disability (modified Rankin Scale score ≥3) at 3 months of randomisation. Antihypertensive treatment will be received immediately after randomisation in the early treatment group, aimed at average systolic BP by 10%–20% reduction within the first 24 hours, and achieving an average BP level of <140/90 mm Hg within 5 days. Patients in the delayed treatment group will discontinue any antihypertension medications for the first 7 days of randomisation, and will receive antihypertensive therapy achieving a BP goal of <140/90 mm Hg after 7 days.Conclusion The CATIS-2 trial will be testing the hypotheses that early BP lowering leads to improved functional outcome without any other harms, and developing clinical guidelines of the BP management for patients who had an acute ischaemic stroke.Trial registration number NCT03479554.